• Complete response rate [ Time Frame: 30 weeks ] [ Designated as safety issue: No ]
  

• Overall response rate [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
  
• Progression-free survival [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
  
• Duration of response [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
  
• Safety of the drug combinations [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
  

Inclusion Criteria:

• Male or female patient 18 years of age or older
• Pathological diagnosis of follicular lymphoma (any grade)
• Documented relapse or progression following prior antineoplastic therapy
• At least 1 measurable tumor mass
• No clinically significant evidence of active central nervous system lymphoma
• Karnofsky performance status - greater than or equal to 50.

• Clinical laboratory values within 21 days prior to enrollment:

  • Absolute neutrophil count - greater than or equal to 1.00 x 10 to the ninth power
  • Platelets - greater than or equal to 100 x 10 to the ninth power for Arm 1 or greater than or equal to 75 x 10 to the ninth power cells for Arm 2.
  • Alanine transaminase less than or equal to 4x upper limit of normal
  • Aspartate transaminase less than or equal to 4x the upper limit of normal
  • Total bilirubin less than 2 x upper limit of normal with a normal direct bilirubin
  • Calculated creatinine clearance greater than or equal to 20 mL/min
• Female patients must be postmenopausal for at least 1 year, surgically sterile, practicing abstinence, or practicing an effective method of birth control.
• Male patients must agree to use an acceptable method of contraception (i.e. a condom) for the duration of the study.
• Patients or the patient's legal representative must have a signed informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study.

Exclusion Criteria:

• Diagnosed or treated for a malignancy other than NHL within 2 years of first dose, or who were previously diagnosed with a malignancy other than NHL and have any radiographic or biochemical marker evidence of malignancy. Patients with prostate cancer who were treated with definitive radiotherapy who have a serum prostate-specific antigen <1 ng/mL are not excluded. Patients are not excluded if they have had basal cell or squamous cell carcinoma of the skin that was completely resected, or any in situ malignancy that was adequately treated.
• Received any of the following treatments or procedures outside of the specified timeframes:
• Prior treatment with VELCADE
• Prior treatment with a cumulative dose of doxorubicin of more than 100 mg/m2, if assigned to Arm A (VELCADE-R-CAP)
• Antineoplastic (including unconjugated therapeutic antibodies and toxin immunoconjugates), experimental, or radiation therapy within 3 weeks before Day 1 of Cycle 1
• Nitrosoureas within 6 weeks before Day 1 of Cycle 1
• Radioimmunoconjugates within 10 weeks before Day 1 of Cycle 1
• Autologous stem cell transplant within 3 months before Day 1 of Cycle 1, or prior allogeneic stem cell transplant at any time
• Major surgery within 2 weeks before Day 1 of Cycle 1
• Residual toxic effects of Grade 2 or worse from previous therapy or surgery
• Peripheral neuropathy of Grade 2 or worse due to any cause
• Known history of HIV infection
• Active systemic infection requiring therapy
• Serious medical or psychiatric illness likely to interfere with participation in this clinical study
• Myocardial infarction within 6 months prior to enrollment or New York Hospital Association Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or significant conduction system abnormalities in the opinion of the investigator
• Residual toxic effects of Grade 2 or worse from previous therapy or surgery
• Peripheral neuropathy of Grade 2 or worse due to any cause
• Known history of HIV infection
• Active systemic infection requiring therapy
• Serious medical or psychiatric illness likely to interfere with participation in this clinical study
• Myocardial infarction within 6 months prior to enrollment or New York Hospital Association Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or significant conduction system abnormalities in the opinion of the investigator